GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cosciens Biopharma Inc (TSX:CSCI) » Definitions » Cyclically Adjusted Price-to-FCF

Cosciens Biopharma (TSX:CSCI) Cyclically Adjusted Price-to-FCF : (As of Jun. 18, 2025)


View and export this data going back to 1992. Start your Free Trial

What is Cosciens Biopharma Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cosciens Biopharma Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Cosciens Biopharma's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosciens Biopharma Cyclically Adjusted Price-to-FCF Chart

Cosciens Biopharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 792.51 - -

Cosciens Biopharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cosciens Biopharma's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Cosciens Biopharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosciens Biopharma's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Cosciens Biopharma's Cyclically Adjusted Price-to-FCF falls into.


;
;

Cosciens Biopharma Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Cosciens Biopharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Cosciens Biopharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-1.139/129.1809*129.1809
=-1.139

Current CPI (Mar. 2025) = 129.1809.

Cosciens Biopharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.172 100.500 -0.221
201509 -0.050 100.421 -0.064
201512 0.541 99.947 0.699
201603 0.470 101.054 0.601
201606 -0.606 102.002 -0.767
201609 0.035 101.765 0.044
201612 0.049 101.449 0.062
201703 -0.766 102.634 -0.964
201706 -0.599 103.029 -0.751
201709 0.277 103.345 0.346
201712 -0.357 103.345 -0.446
201803 0.022 105.004 0.027
201806 -0.225 105.557 -0.275
201809 -0.568 105.636 -0.695
201812 -1.051 105.399 -1.288
201903 0.165 106.979 0.199
201906 0.266 107.690 0.319
201909 0.112 107.611 0.134
201912 -0.235 107.769 -0.282
202003 0.274 107.927 0.328
202006 1.157 108.401 1.379
202009 1.047 108.164 1.250
202012 -0.273 108.559 -0.325
202103 0.018 110.298 0.021
202106 1.108 111.720 1.281
202109 0.076 112.905 0.087
202112 0.260 113.774 0.295
202203 0.613 117.646 0.673
202206 1.375 120.806 1.470
202209 0.718 120.648 0.769
202212 0.758 120.964 0.809
202303 -0.637 122.702 -0.671
202306 -0.624 124.203 -0.649
202309 0.069 125.230 0.071
202312 -1.214 125.072 -1.254
202403 -2.156 126.258 -2.206
202406 -0.955 127.522 -0.967
202409 -3.448 127.285 -3.499
202412 -1.501 127.364 -1.522
202503 -1.139 129.181 -1.139

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cosciens Biopharma  (TSX:CSCI) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Cosciens Biopharma Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Cosciens Biopharma's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosciens Biopharma Business Description

Industry
Traded in Other Exchanges
Address
c/o Norton Rose Fulbright Canada LLP, 222 Bay Street, Suite 3000, P.O. Box 53, Toronto, ON, CAN, M5K 1E7
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology. The Company has two reportable and operating segments: Active ingredient and Biopharmaceutical.
Executives
Dennis Turpin Director
Gilles Gagnon Director